放疗治疗 III 期非小细胞肺癌中 GLUT1 基因变异的预后意义。
Prognostic significance of genetic variants in GLUT1 in stage III non-small cell lung cancer treated with radiotherapy.
机构信息
Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, South Korea.
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
出版信息
Thorac Cancer. 2021 Mar;12(6):874-879. doi: 10.1111/1759-7714.13851. Epub 2021 Jan 31.
BACKGROUND
To examine the impact of polymorphisms of glucose transporter 1 (GLUT1) gene on the prognosis of patients with stage III non-small cell lung cancer (NSCLC) who received radiotherapy.
METHODS
Five single nucleotide polymorphisms (SNPs) (rs4658C>G, rs1385129G>A, rs3820589A>T, rs3806401A>C and rs3806400C>T) in GLUT1 gene were evaluated in 90 patients with pathologically confirmed stage III NSCLC. A total of 21 patients were treated with radiotherapy alone, 25 with sequential chemoradiotherapy, and 44 with concurrent chemoradiotherapy. The association of the genetic variations of five SNPs with overall survival (OS) and progression-free survival (PFS) was analyzed.
RESULTS
Two SNPs (rs1385129 and rs3806401) were significant risk factors for OS. Three SNPs (rs1385129, rs3820589 and rs3806401) were in linkage disequilibrium. In Cox proportional hazard models, GAA haplotype was a good prognostic factor for OS (hazard ratio [HR] = 0.57, 95% confidence interval [CI]: 0.39-0.81, p = 0.002) and PFS (HR = 0.68, 95% CI: 0.47-0.99, p = 0.043), compared to variant haplotypes. The GAA/GAA diplotype was observed in 46.7% of patients; these patients showed significantly better OS (HR = 0.38, 95% CI: 0.22-0.65, p < 0.001) and PFS (HR = 0.51, 95% CI: 0.31-0.85, p = 0.009) compared to those with other diplotypes.
CONCLUSIONS
These results suggest that polymorphisms of GLUT1 gene could be used as a prognostic marker for patients with stage III NSCLC treated with radiotherapy.
背景
研究葡萄糖转运蛋白 1（GLUT1）基因多态性对接受放疗的 III 期非小细胞肺癌（NSCLC）患者预后的影响。
方法
在 90 例经病理证实的 III 期 NSCLC 患者中，评估 GLUT1 基因中的 5 个单核苷酸多态性（SNP）（rs4658C>G、rs1385129G>A、rs3820589A>T、rs3806401A>C 和 rs3806400C>T）。21 例患者接受单纯放疗，25 例患者接受序贯放化疗，44 例患者接受同步放化疗。分析 5 个 SNP 遗传变异与总生存期（OS）和无进展生存期（PFS）的相关性。
结果
rs1385129 和 rs3806401 两个 SNP 是 OS 的显著危险因素。三个 SNP（rs1385129、rs3820589 和 rs3806401）存在连锁不平衡。在 Cox 比例风险模型中，GAA 单倍型是 OS（风险比[HR] = 0.57，95%置信区间[CI]：0.39-0.81，p = 0.002）和 PFS（HR = 0.68，95% CI：0.47-0.99，p = 0.043）的良好预后因素，与变异单倍型相比。GAA/GAA 二倍型在 46.7%的患者中观察到；与其他二倍型相比，这些患者的 OS（HR = 0.38，95% CI：0.22-0.65，p < 0.001）和 PFS（HR = 0.51，95% CI：0.31-0.85，p = 0.009）显著更好。
结论
这些结果表明，GLUT1 基因多态性可作为接受放疗的 III 期 NSCLC 患者的预后标志物。
Zotero 插件